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Abstract
Abnormal alterations in cardiac expression of vascular endothelial growth factor (VEGF) as well as its 
receptors and impairment in the development of coronary collaterals have recently been reported in 
diabetic subjects. However, the pres- ence of pharmacological intervention on these defects in diabetes 
remains unsettled. Here, we studied the effect of endothelin (ET) receptor blockade on cardiac VEGF 
signaling pathways and cardiac function in Sprague-Dawley rats 5 wk after induction of type I diabetes 
with streptozotocin (65 mg/kg ip) in comparison with age- matched control rats. After streptozotocin (1 
wk), some diabetic rats were treated with the ET receptor antagonist SB-209670 (1 mg/day) for 4 wk. 
VEGF, its receptors, and its angiogenic signaling molecules [phosphorylated Akt and endothelial nitric-
oxide synthase (eNOS)] were analyzed by Western blot, ELISA, real-time PCR, and immu- 
nohistochemistry, and cardiac function was evaluated by echocardi- ography. Coronary capillary 
morphology was assessed by lectin and enzymatic double staining. We found significant decreases in 
cardiac expression of VEGF, its receptors, phosphorylation of Akt and eNOS, and coronary capillary 
density in diabetic rats compared with controls. Treatment of diabetic rats with SB-209670 reversed these 
alterations to the control levels and ameliorated impairment of cardiac function. From a molecular point of 
view, the present study is the first to indicate the potential usefulness of an ET receptor antagonist in the 
treatment of cardiac dysfunction in type I diabetes. 
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DIABETES MELLITUS is associated with macro- and microvascular 
complications in multiple organ systems (11). A large body of 
epidemiological and pathological data demonstrate that diabe- 
tes is an independent risk factor for cardiovascular disease in 
both men and women (11), and coronary artery disease is 
considered the leading cause of morbidity and mortality in 
patients with diabetes (12). 
Vascular endothelial growth factor (VEGF), an endothelial 
cell-specific mitogen that is important in neovascularization 
under both physiological and pathophysiological conditions, 
plays a crucial role in developmental blood vessel formation 
and regulation of hypoxia-induced tissue angiogenesis (2, 9). 
The following two high-affi VEGF tyrosine kinase re- 
ceptors  have  been  identifi fms-like  tyrosine  kinase  1 
(Flt-1) and fetal liver kinase 1 (Flk-1), both of which are 
expressed  almost  exclusively  in  endothelial  cells  (39).  A 
signifi increase in VEGF levels can be observed after 
myocardial infarction in nondiabetic patients (46), conse- 
quently leading to the development of collateral vessels in 
the  advanced  stages  of  coronary  atherosclerosis  (1).  In 
diabetic  patients,  however,  there  is  inadequate  collateral 
vascular formation in response to ischemia that ultimately 
results in increased cardiovascular morbidity and mortality 
rates  (1).  Thus  diabetic  patients  suffering  from  coronary 
artery disease have a less favorable outcome compared with 
nondiabetic patients, including a three- to fourfold increase 
in mortality risk (48, 50). Interestingly, a previous study 
showed  that  myocardial  expression  levels  of  mRNAs  for 
VEGF and its receptors, Flt-1 and Flk-1, were signifi 
decreased in nonischemic short-term streptozotocin-induced 
diabetic rats, and a twofold reduction in VEGF and Flk-1 
was observed in autoptic ventricular specimens from dia- 
betic patients compared with nondiabetic subjects who died 
from myocardial infarction (6). 
Evidence is now strong for a role of endothelin (ET)-1, a potent 
vasoconstrictor with vasoproliferative activity (35), in diabetes. 
Plasma ET-1 levels have been shown to be elevated in animal 
models of diabetes mellitus (14, 30, 51) and in diabetic patients (8, 
37). Furthermore, it has been reported that activity of endogenous 
ET-1 on ETA receptors is enhanced in the resistance vessels of 
diabetic patients (3). Thus the ET system appears to play a key 
role in the development of cardiovascular complications associ- 
ated with diabetes and, therefore, therapy with intervention de- 
signed to suppress the ET system may prevent the development of 
cardiovascular complications in diabetes. 
In the present study, we found downregulated cardiac ex- 
pression levels of VEGF and its receptors, impaired cardiac 
VEGF signaling, decreased coronary capillary density, and 
cardiac dysfunctions in rats with 5 wk of streptozotocin- 
induced diabetes. Diabetic rats exhibited a significant increase 
in ET-1 in left ventricular (LV) tissues compared with nondi- 
abetic controls. The final goal of this study was to determine 
whether treatment with SB-209670, which is an antagonist 
against both ETA and ETB receptors, can improve deteriora- 
tions of the VEGF signaling pathways, coronary capillary 
morphology, and cardiac functions in diabetic rats. 
MATERIALS AND METHODS 
Experimental animals. Male Sprague-Dawley rats (10  wk  and 
200 –250 g body wt) were used in this study. After an overnight fast, 
the animals received a single intraperitoneal injection of streptozoto- 
cin (65 mg/kg). Streptozotocin was dissolved in a citrate solution (0.1 
M citric acid and 0.2 M sodium phosphate, pH 4.5). Control rats (n = 
26) received an equivalent volume of citrate buffer alone. All animals
injected with streptozotocin developed diabetes, as indicated by 
plasma glucose levels >250 mg/dl (Glucometer Elite; Bayer) at 48 h 
following the injection. After the streptozotocin injection (1 wk), 
diabetic animals were randomly divided into two groups. One group 
of diabetic rats (n = 20) was given SB-209670 (SmithKline Beecham 
Pharmaceuticals) at a dose of 1 mg/day for 4 wk subcutaneously 
through an osmotic pump that was implanted in the back. Another 
group (n = 27) was given the physiological saline alone. Treatment 
with SB-209670 for 4 wk was also conducted on some control rats. 
All rats were fed with the same diet and water until they were used 4 
wk later. All animal procedures were reviewed and approved by the 
Animal Experiment Committee at the University of Tsukuba. 
Morphometric analysis. Frozen sections of LV (8 µm thick) were 
stained with lectin Griffonia simplicifolia (20). For visualization, 
3,3-diaminobenzidine/H2O2 was used as chromogen. Vascular endo- 
thelium was stained with lectin with capillaries appearing as black or 
dark brown dots. Sections were examined with an Olympus micro- 
scope, and counts of capillaries were made in 30 square fields/sample 
at a final magnification of X400. 
Double staining of sections was carried out to discriminate arterio- 
lar and venular capillaries, as previously described (22). Sections (16 
µm thick) cut from the frozen LV at the widest part were used. 
Western blot analysis. LV tissues were homogenized with 10 vol of 
20 mM Tris · HCl (pH 7.4), 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 
1 mM Na3VO4, 2 mM dithiothreitol, 20 mM glycerophosphate, 0.6% 
Nonidet P-40, 0.5 mM phenylmethylsulfonyl fl 60 µg/ml aproti- 
nin, and 1 µg/ml leupeptin on ice using a homogenizer. The homogenate 
was gently rotated for 30 min at 4°C and then centrifuged at 13,000 g for 
10 min at 4°C, and the protein concentration of the resulting supernatant 
was determined. The samples (20 µg of protein) were then subjected to 
heat denaturation at 96°C for 7 min with Laemmli buffer. Western blot 
analysis for detection of phosphorylated and nonphosphorylated forms of 
different target molecules was performed according to the method de- 
scribed in previous studies with minor modifi  (15, 18, 25, 28, 45, 
52). Briefl each sample was separated on 10% SDS-polyacrylamide gel 
and transferred to a polyvinylidene difl (Millipore, Billerica, MA) 
membrane. The membrane was incubated in blocking buffer with 5% 
skim milk in PBS containing 0.1% Tween 20 for 12 h at 4°C, followed 
by incubation with primary antibody for 1 h at room temperature. The 
membrane was washed with PBS containing 0.1% Tween 20 three times 
and incubated with horseradish peroxidase-conjugated secondary anti- 
body, which was an anti-rabbit, anti-mouse, or anti-goat IgG (1:2,000 
dilution with blocking buffer; Cell Signaling, Beverly, MA), for 1 h at 
room temperature. After being washed, as described above, the expres- 
sion level of each molecule was determined using enhanced chemilumi- 
nescence detection reagents (Amersham Pharmacia Biotech, Piscataway, 
NJ) followed by exposure to Hyper fi     (Amersham Biosciences). 
The following antibodies, which are commercially available, were 
used: rabbit antihuman VEGF polyclonal antibody (Immunological 
Laboratories, Fujioka, Japan), rabbit antihuman Flk-1 polyclonal an- 
tibody (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit antihuman 
Flt-1 polyclonal antibody (Santa Cruz Biotechnology), rabbit antihu- 
man endothelial nitric oxide synthase (eNOS) polyclonal antibody 
(Affinity BioReagents, Golden, CO), rabbit polyclonal phosphory- 
lated Akt (Ser473) antibody (Cell Signaling Technology), rabbit poly- 
clonal Akt antibody (Cell Signaling), Ser1177-phospho-eNOS (Santa 
Cruz Biotechnology), rabbit polyclonal phospho-Flk-1 (Tyr951) anti- 
body (Santa Cruz Biotechnology), and rabbit polyclonal phospho- 
Flk-1 (Tyr996) antibody (Santa Cruz Biotechnology). 
Immunoprecipitation and immunoblotting for phospho-Flk-1. Ali- 
quots of protein lysates were obtained as described in previous studies 
(28, 45, 52). Protein extracts were incubated overnight at 4°C with 3 
µg of rabbit polyclonal anti-Flk-1 (Santa Cruz Biotechnology). Sub- 
sequently, 50 µl of protein A-agarose were added. Immunoprecipi- 
tated proteins were separated on 8% sodium-dodecyl-(lauryl)-sulfate- 
PAGE, transferred to nitrocellulose filters, and exposed to rabbit 
polyclonal anti-phospho-Flk-1 (Santa Cruz Biotechnology; see Refs. 
28, 45, and 52). 
Immunoassay. Analysis of the levels of VEGF and eNOS in LV 
tissues was also performed using the ELISA-based immunoassay kits 
(R&D Systems, Minneapolis, MN) according to the manufacturer’s 
instructions. The level of Akt protein, which was phosphorylated at 
serine residue 473, in LV tissue extract, was quantitatively determined 
by an ELISA kit, AKT [pS473] (BioSource International). Concen- 
trations of ET-1 in tissue extracts were determined using an ET-1 
Enzyme Immuno Assay Kit (Immuno-Biological Laboratories). 
Immunofluorescence and confocal analysis. For immunohisto- 
chemical determination of target molecules, the tissue sections were 
exposed to the fluorescent secondary antibody after overnight incu- 
bation with each primary antibody, as fully described in our previous 
reports (24, 25). Immunofluorescent images were observed under 
Laser Scanning Confocal Imaging System (24, 25). Phosphorylated 
eNOS and phosphorylated Akt were purchased from Santa Cruz 
Biotechnology and Cell Signaling Technology, respectively. 
RNA preparation and real-time quantitative PCR. Total RNA was 
extracted from LV tissues by the guanidinium thiocyanate-phenol- 
chloroform single-step extraction method with ISOGEN (Nippon 
Gene). The single-stranded cDNA was used in real-time quantitative 
PCR for evaluation of relative expression levels of target genes. We 
have previously described the primers and conditions used for real- 
time quantitative PCR analyses (24, 25). 
Echocardiography. Rats were anesthetized with pentobarbital so- 
dium (40 mg/kg ip), and LV fractional shortening (FS) and stroke 
volume (SV) was measured using a Doppler-echocardiographic sys- 
tem (SONOS 4500; Koninklijke Philips Electronics), as described in 
our previous report with minor modification (16). We determined the 
heart rate, LV end-diastolic diameter (LVEDD), LV end-systolic 
diameter (LVESD), LVFS, which was calculated according to the 
following formula: LVFS (%) = [(LVEDD - LVESD)/LVEDD] X 
100, and diameter of the ascending aorta at end-diastole with a 12-
MHz transducer using M-mode echocardiography. Doppler ultra- 
sonographic flow velocity curves in the ascending aorta were simul- 
taneously recorded, and mean blood velocity throughout a cardiac 
cycle was determined by planimetry (Image J; National Institutes of 
Health). SV was calculated as a product of the velocity integral and 
aortic cross-sectional area. Furthermore, cardiac output (CO) was 
calculated as the product of the SV and heart rate. After the echocar- 
diographic measurements, a microtip pressure transducer catheter 
(SPC-320; Millar Instruments) was inserted in the left carotid artery. 
Arterial blood pressure was monitored with a pressure transducer 
(model SCK-590; Gould) and was recorded with the use of a poly- 
graph system (Nihon Kohden, Tokyo, Japan). After measurement, the 
catheter was advanced in the LV for the determination of LV systolic 
pressure (LVSP) and LV end-diastolic pressure (LVEDP), as previ- 
ously described (42). 
Statistical analysis. Data are reported as means ± SD. Statistical 
analyses were performed using one-way ANOVA, and post hoc 
comparisons were made with Fisher’s protected least-significance t-
test for multiple comparisons. A P value of <0.05 was considered 
significant. 
RESULTS 
Characteristics of experimental animals. The general fea- 
tures of diabetic rats treated with SB-209670 or its vehicle and 
age-matched control animals are summarized in Table 1. Body 
weight was significantly decreased in diabetic rats, and treat- 
ment with SB-209670 had no effect on the diabetes-induced 
weight loss. The fed plasma glucose levels in diabetic rats were 
elevated ~4.5-fold compared with controls. On the other hand, 
their plasma insulin levels were extremely lower than controls. 
Treatment of diabetic rats with SB-209670 for 4 wk did not 
alter hyperglycemia and hypoinsulinemia. LV weight was 
significantly decreased in diabetic rats compared with controls 
and was unaffected by SB-209670 treatment. The LV weight- 
to-body weight ratio was significantly higher in diabetic rats, 
which was significantly reversed by SB-209670 treatment. 
Blood pressure was not significantly different among the 
groups of animals. 
These experimental diabetic rats exhibited severe glycosuria 
(250 –500 mg/dl) that was not improved by SB-209670, 
whereas no study group showed urinary protein excretion. A 
10-fold increase in the 24-h urinary volume was observed in 
diabetic rats, which was not affected by SB-209670. All 
diabetic animals survived throughout the study period regard- 
less of whether SB-209670 was used. 
The ET-1 level in LV tissues as determined by ELISA was 
significantly elevated in diabetic rats (2.1 ± 0.3 pg/mg, n = 
17) compared with controls (1.4 ± 0.2 pg/mg, n = 17).
Expression of VEGF and its receptors. ELISA and Western 
blot analysis showed a 40% decrease in VEGF protein after 5 
wk of diabetes compared with nondiabetic controls (Fig. 1, A 
and B). The ELISA kit applied in the present study recognizes 
both the 165- and 121-amino acid residue forms of VEGF. The 
present study used the following two antibodies for immuno- 
detection of VEGF: anti-human VEGF mouse monoclonal 
antibody (Santa Cruz Biotechnology) and anti-human VEGF 
rabbit polyclonal antibody (Immunobiological Laboratories, 
Fujioka, Japan). Both of the antibodies could detect VEGF at 
46 kDa and VEGF monomer at 23 kDa. We thus revealed the 
data obtained with anti-human VEGF rabbit polyclonal anti- 
body, which is specific for human, rat, and mouse. In fact, 
Table 1. General and hemodynamic characteristics of 
experimental rats 
Fig. 1. Protein and gene expression levels of vascular endothelial growth 
factor (VEGF) in left ventricular (LV) tissues of nondiabetic control, diabetic, 
and SB-209670-treated diabetic rats. ELISA (A) and Western blot analysis (B) 
were performed for protein expression. For immunoblot analysis, in each of the 
experiments, the band obtained in the nondiabetic control is normalized to 1.0. 
C: total RNA isolated from LV was analyzed by real-time quantitative PCR. 
Values are means ± SD. P < 0.05 vs. nondiabetic control (*) and vs. diabetic 
(†); n = 17 rats. 
Values are means ± SD; n, no. of rats. LV, left ventricular; SBP and DBP, 
systolic and diastolic blood pressure, respectively; LVSP and LVEDP, mean 
LV systolic and LV end-diastolic pressure, respectively; LVEDD and LVESD, 
LV end-diastolic and LV end-systolic diameter, respectively; IVST and PWT, 
mean interventricular septal thickness and posterior wall thickness, respec- 
tively. P < 0.05 vs. control (*) and vs. diabetic (†). 
human VEGF165 is typically expressed as a 46-kDa ho- 
modimer of 23-kDa monomers and is the major, most abun- 
dant, and most biologically active form of VEGF (39, 40). A 
similar reduction was also observed at its gene level in LV of 
diabetic rats, which was obtained from real-time quantitative 
Parameters 
Body wt, g 
Plasma glucose, mg/dl 
Plasma insulin, ng/ml 
LV wt, mg 
LV wt-to-body wt, mg/g
Control 
(n = 10) 
Diabetic 
(n = 13) 
Diabetic with 
SB-209670 
(n = 13) 
503±55 350±42* 361±38* 
120±10 534±78* 535±79* 
7.94±2.44 0.32±0.30* 0.24±0.17* 
851±81 687±143* 716±66* 
1.59±0.11 2.31±0.35* 1.83±0.14† 
SBP, mmHg 121±13 116±13 118±9 
DBP, mmHg 93±11 86±10 86±26 
LVSP, mmHg 112±21 106±12 108±6 
LVEDP, mmHg 2.1±1.8 7.2±2.4* 4.4±1.7† 
Heart rate, beats/min 360±39 337±18 336±22 
LVEDD, mm 6.47±0.32 6.58±0.41 6.67±0.45 
LVESD, mm 3.76±0.14 4.18±0.35* 3.97±0.31 
IVST, mm 1.1±0.1 1.0±0.1 1.1±0.1 
PWT, mm 1.3±0.2 1.2±0.2 1.2±0.1 
Stroke volume, ml 0.48±0.02 0.41±0.08* 0.48±0.06† 
PCR (Fig. 1C). Treatment with SB-209670 for 4 wk normal- 
ized LV expression of VEGF at both protein and mRNA levels. 
On immunoblots, LV expression levels of Flk-1 and Flt-1 
proteins were reduced by 42 and 33%, respectively, in diabetic 
rats (Fig. 2, A and C). The decrease in protein expression of 
these VEGF receptors in LV of diabetic rats correlated with 
their mRNAs (Fig. 2, B and D). SB-209670 treatment greatly 
ameliorated  downregulation  of  the  two  VEGF  receptors  in 
diabetes. 
VEGF signaling pathways. As shown in Fig. 3, the phos- 
phorylation level of the VEGF angiogenic receptor, Flk-1, was 
significantly lower in LV tissues of diabetic rats than in 
controls. The decrease in the phosphorylated Flk-1 level was 
completely reversed by SB-209670 treatment. In the present 
study, both expression levels of phosphorylated and nonphos- 
phorylated Flk-1 were decreased in the diabetic heart, which 
was consistent with the previous report (45). In addition, when 
we calculated the ratio of phospho-Flk-1 to Flk-1, this ratio 
was also significantly decreased in diabetic heart compared 
with the nondiabetic control and was significantly reversed by 
SB-209670 (Fig. 3). Two rabbit polyclonal antibodies raised 
against COOH terminus and against amino acids 931–997 of 
Flk-1 were used in this study, and the combined data from 
these antibodies are presented in Fig. 2A. Flk-1 is activated 
through ligand-stimulated receptor dimerization and trans(au- 
to)phosphorylation of at least six tyrosine residues as follows: 
Tyr951 and Tyr996 in the kinase insert; Tyr1054 and Tyr1059 in 
the kinase domain; and Tyr1175 and Tyr1214 in the COOH- 
terminal tail (27, 39, 58). The present study detected the 
phosphorylation level at Tyr951 and Tyr996 sites, and the data 
presented in Fig. 3 were the combined data from both of the 
antibodies. 
The results of immunoblot analysis revealed that total pro- 
tein expression of Akt, a downstream effecter of VEGF, was 
unchanged by diabetes. However, the phosphorylated level of 
Akt was significantly diminished in diabetic rats. The decrease 
in Akt phosphorylation in diabetic LV tissues was also con- 
firmed by analysis using the ELISA method (data not shown). 
We found a substantial reduction in the phosphorylated level of 
eNOS in diabetic LV tissues without any significant change in 
Fig. 2. Protein and gene expression levels of fetal liver kinase 1 (Flk-1; A and B) and fms-like tyrosine kinase 1 (Flt-1; C and D) in LV tissues of nondiabetic 
control, diabetic, and SB-209670-treated diabetic rats. Western blot analysis was performed for protein expression, and immunoreactive Flk-1 (A) and Flt-1 (C) 
were detected as a single band with a molecular mass of 200 and 180 kDa, respectively. For immunoblot analysis, in each of the experiments, the band obtained 
in the nondiabetic control is normalized to 1.0. Total RNA isolated from LV was analyzed by real-time quantitative PCR (B and D). Values are means ± SD. 
P < 0.05 vs. nondiabetic control (*) and vs. diabetic (†); n = 17. 
Fig. 3. Analysis of Flk-1, Akt, and endothelial nitric oxide synthase (eNOS) phosphorylation in LV tissues of nondiabetic control, diabetic, and SB-209670- 
treated diabetic rats. Protein phosphorylation was analyzed by Western blot using phosphospecific antibodies. A: representative blots. Protein loading was verified 
using anti-[3-actin antibodies. B: densitometric results. In each of the experiments, the band obtained in the nondiabetic control is normalized to 1.0. Values are 
means ± SD. *P < 0.05 vs. nondiabetic control; †P < 0.001 vs. diabetic; n = 17. 
total eNOS expression. Treatment with SB-209670 normalized 
the decreased phosphorylation levels of Akt and eNOS ob- 
served in diabetic LV tissues. Immunofluorescence studies 
showed that phosphorylated Akt and phosphorylated eNOS 
were evidently reduced in endothelial cells of coronary vessels 
from diabetic rats compared with controls and the reductions 
were sharply ameliorated by SB-209670 treatment (Fig. 4). 
Morphological data. The coronary capillary morphology 
obtained from lectin staining represented that streptozotocin- 
induced diabetes resulted in an evident reduction in coronary 
capillaries in LV sections (Fig. 5A). The total capillary density 
determined by the lectin method showed a 25% reduction in 
diabetes (Fig. 5B). Treatment of diabetic rats with SB-209670 
significantly improved the capillary density to the control level. 
Fig. 4. Representative immunofluorescence images for phosphorylated Akt (pAkt) and phosphorylated eNOS (peNOS) in LV cross sections from nondiabetic 
control, diabetic, and SB-209670-treated diabetic rats from immunofluorescent staining. Positive staining was focused on coronary vessels. Magnification X200. 
Figure 4C shows representative micrographs of coronary cap- 
illaries of LV sections in control, diabetic, and SB-209670- 
treated diabetic rats obtained by the double-staining method. 
The venular capillary portion, which stained red, was evidently 
remarkable in control rats, whereas the intermediate and arte- 
riolar capillary portions, which stained violet and blue, respec- 
tively, were much pronounced in diabetic rats. Treatment of 
diabetic rats with SB-209670 evidently reversed the decreased 
portion of venular capillaries in diabetic rats. 
Cardiac functions assessed by echocardiography. Represen- 
tative M-mode echocardiograms of control, diabetic, and SB- 
209670-treated diabetic rats are shown in Fig. 6. LVFS and CO 
were significantly lower in diabetic rats compared with con- 
trols (Fig. 6, B and C). Treatment of diabetic rats with SB- 
209670 significantly ameliorated these cardiac function param- 
eters. Although no significant difference was found in LVEDD 
and LVSP between control and diabetic rats, LVESD and 
LVEDP were significantly higher in diabetic animals and were 
improved to the control level by SB-209670 treatment (Table 
1). Interventricular septal thickness and posterior wall thick- 
ness were almost the same among different experimental rats 
(Table 1). Treatment of nondiabetic control rats with SB- 
209670 did not significantly affect any parameters of cardiac 
functions (n = 5, data not shown). 
DISCUSSION 
The present study demonstrated that cardiac expression of 
VEGF and its receptors was downregulated, cardiac VEGF 
signaling was impaired, the coronary capillary density was 
decreased, and cardiac function went down in rats with 5 wk of 
streptozotocin-induced diabetes compared with age-matched 
nondiabetic control animals. The present study for the first time 
provides a comprehensive investigation of the VEGF, VEGF 
receptors, and the downstream molecules of VEGF angiogenic 
signaling (Akt and eNOS) with the morphometric evaluation of 
coronary capillary network in the early streptozotocin-induced 
diabetic heart, although some studies have already investigated 
the VEGF and its receptor expression in streptozotocin-in- 
duced diabetic hearts of various durations. In addition, the key 
data from this study provide substantial evidence as to the 
importance of the ET system in the pathogenesis of these 
cardiac deteriorations in diabetes. We thus showed that altered 
VEGF signaling pathways and reduced coronary capillaries as 
well as cardiac dysfunctions were nearly completely prevented 
by treatment of diabetic animals with the mixed ETA and ETB 
receptor antagonist SB-209670. 
There has been increasing research interest in understanding 
the impact of diabetes on coronary vascular function, and 
diabetes is identified as one of the first negative predictors of 
collateral vessel formation (1). The presence and extent of 
coronary collateral circulation may have prognostic relevance 
for individual patients, in terms of the outcome of coronary 
events (1). For instance, adequate collateral vessels in myocar- 
dium at risk may limit the size of infarct following coronary 
occlusion and, consequently, improve the prognosis (1). Be- 
cause VEGF is known to play an essential role in angiogenesis 
(9), VEGF may participate in promoting the formation of new 
capillaries from preexisting coronary vessels under some 
pathological conditions. We found a significant downregula- 
tion of VEGF and its receptors, Flk-1 and Flt-1, in LV tissues 
of streptozotocin-induced diabetic rats. Previous work from 
another laboratory has also shown that, with the use of RT- 
PCR or Northern blot, cardiac gene expression of VEGF and 
its receptors is significantly decreased in streptozotocin-in- 
duced diabetic rats as well as established diabetic patients with 
hypertension and/or myocardial infarction (6). Moreover, the 
present study represents the first report that Flk-1 phosphory- 
lation and Akt phosphorylation, both of which are an important 
event in VEGF signaling, were significantly impaired in strep- 
tozotocin-induced diabetic cardiac tissues. VEGF activates Akt 
via a phosphatidylinositol 3'-kinase (PI 3-kinase)-dependent 
pathway, and this downstream effecter may play a key role in 
the “hallmark” biological processes of VEGF, such as endo- 
thelial cell proliferation, migration, and survival (7, 47). Al- 
 
Fig. 5. Evaluations of morphologically existing coronary capillaries in LV sections of nondiabetic control, diabetic, and SB-209670-treated diabetic rats. A: 
photomicrographs showing capillaries detected by staining the endothelium with lectin. Magnification X400. B: bar graph summarizing the total capillary density, 
obtained by the lectin staining method. Values are means ± SD (30 fields X 17 samples). P < 0.05 vs. nondiabetic control (*) and vs. diabetic (†). C: 
photomicrographs of subendocardial LV sections. Arteriolar, intermediate, and venular capillaries were stained blue, violet, and red, respectively (see arrows). 
Magnification X400. 
though the PI 3-kinase/Akt signal transduction pathway regu- 
lates angiogenesis, Akt may be important in vascular ho- 
meostasis through eNOS activation (38). Thus Akt-dependent 
phosphorylation of eNOS is indicated to mediate the effects of 
VEGF on endothelial cells (10). We found a significant reduc- 
tion in the phosphorylation level of eNOS in diabetic rat hearts. 
Various distribution patterns of eNOS may be seen in heart 
tissues from diabetic subjects in different studies. In the pre- 
vious study, we have shown that, in a type 2 insulin-resistant 
diabetic rat model that exhibits modest hyperglycemia but 
strong insulin resistance, eNOS expression was increased in 
coronary vessels by immunohistochemistry compared with the 
nondiabetic control (21). In the present study, the ratio of 
phospho-eNOS to total eNOS was decreased in streptozotocin- 
induced diabetic hearts although the total eNOS protein ex- 
pression was almost unchanged. In another study, at 12 and 24 
wk after streptozotocin-induced diabetes, the eNOS level in the 
heart tissue was significantly decreased (49). Thus we specu- 
late that eNOS protein expression in the heart may be dimin- 
ished with the progression of type 1 diabetes. 
The exact mechanisms triggering the alterations in cardiac 
VEGF signaling in diabetes remains an open question. How- 
ever, insulin deficiency may be suggested as one of the poten- 
tial mechanisms because insulin can induce VEGF expression 
Fig. 6. A: representative M-mode echocardiograms of nondiabetic control, diabetic, and SB-209670-treated diabetic rats. A two-dimensional short-axis view was 
recorded at the level of papillary muscle. B and C: summarized data for LV fractional shortening (LVFS) and cardiac output (CO) measured by echocardiography. 
Values are means ± SD. P < 0.05 vs. nondiabetic control (*) and vs. diabetic (†); n = 10 –13. 
(34). In different cell types, insulin has been shown to increase 
VEGF mRNA expression by activating the PI 3-kinase/Akt 
pathway (34). Intriguingly, contrary to the results obtained in 
streptozotocin-induced diabetic rats, a very recent study 
showed increased expression of VEGF but decreased expres- 
sion of its receptors and signaling pathway in cardiac tissues of 
type 2 diabetic patients with chronic coronary artery disease 
(45). The reason for this apparent discrepancy is not clear but 
may be related to the possibility that plasma and tissue insulin 
levels may have been greatly elevated in type 2 diabetic 
patients in association with their insulin resistance. 
The morphometric analysis showed arterialization of the 
venular capillary portion. Because capillary angiogenesis usu- 
ally initiates from the venular site, the lower proportion of 
venular capillaries resulted in decreased capillary density in 
streptozotocin-induced rat hearts. Cardiac VEGF signaling 
may be involved in the angiogenic changes in the coronary 
capillary network. Therefore, in streptozotocin-induced dia- 
betic rats, diminished VEGF signaling in the heart may be 
responsible for the decreased capillary density. 
Generally, in diabetic rat models, cardiac function appears to 
deteriorate in proportion to the duration of diabetes. However, 
cardiac dysfunction may be observed even at the prediabetic 
stage. Indeed, abnormal LV diastolic function has been found 
from the prediabetic state in Otsuka Long-Evans Tokushima 
Fatty rats, a model of human type 2 diabetes (36). In the 
present study, both systolic and diastolic dysfunction were 
evident in rats with 5 wk of streptozotocin-induced diabetes, 
although cardiac function appears to be depressed from a more 
early term in this diabetic model (19). The relationship be- 
tween VEGF/VEGF receptor expression, microvascular integ- 
rity, and cardiac function has been demonstrated most vividly 
in experiments using transgenic mice lacking VEGF isoforms, 
VEGF164 and VEGF188 (4). These transgenic animals exhibit 
impaired myocardial angiogenesis, leading to the development 
of severe LV dysfunction (4). Direct intramyocardial gene 
transfer of plasmid DNA encoding human VEGF165, which can 
replenish myocardial VEGF expression, could result in in- 
creased capillary density and thus improved myocardial func- 
tion in the streptozotocin-induced diabetic rat model (57). 
However, to date, no pharmacological approach has been 
known to restore microvascular homeostasis and to recover 
cardiac function in diabetic cardiomyopathy. The present study 
represents the first evidence that ET receptor antagonist ther- 
apy can normalize VEGF signaling, coronary capillary density, 
and cardiac functions in diabetic rats. 
We showed that the ET-1 level in LV tissues was 1.5-fold 
higher in diabetic than in control rats. In diabetes, the change 
in balance of endothelial mediators released by endothelium 
may shift to ANG II and ET, substances that enhance prolif- 
eration of smooth muscle cells and limit the coronary reserve 
of myocardium (41). The expression levels of ET-1 and its 
receptors have been documented to be augmented in the hearts 
of rats with both short and long terms of streptozotocin- 
induced diabetes (5, 29, 54). Finally, chronic ET receptor 
blockade with bosentan has been shown to improve functional 
cardiac performance in streptozotocin diabetic rats of more 
prolonged duration (53). A growing body of evidence thus has 
suggested that alterations in the ET system have a significant 
role in the pathogenesis of diabetic heart disease (5, 54). 
The interaction between VEGF and ET-1 in vascular endo- 
thelial and smooth muscle cells is well documented (33). ET-1 
and VEGF apparently play a complementary and coordinated 
role during neovascularization and malignant ascite formation 
in ovarian carcinoma (44). The endothelial autocrine regula- 
tory role of ET-1 as a putative angiogenic factor in the process 
of neovascularization has been recently reported (43). In con- 
trast with those reports, ET receptor blockade with bosentan 
shows a marked proangiogenic effect in an ischemic leg after 
femoral occlusion, and this effect appears to be directly depen- 
dent on the VEGF/eNOS pathways (17). Bosentan was con- 
sidered to modulate ischemia-induced angiogenesis by increas- 
ing the speed of revascularization and maintaining sustained 
activation of the process (17). However, several lines of evi- 
dence suggest cell mitogen and proliferating effects of ET-1 in 
in vitro studies (13, 55, 56). We clearly demonstrate that ET 
receptor blockade with SB-209670 normalizes declined cardiac 
VEGF angiogenic signaling and thus impaired coronary cap- 
illary morphology in diabetic rats. In diabetes, plural stimuli 
may be involved in the angiogenic response, depending on the 
tissue type or organ investigated. Future studies should aim to 
shed light to the mechanistic insight underlying the improve- 
ment of the declined cardiac VEGF signaling by ET receptor 
antagonism in diabetes. In the present study, blood pressure 
was unchanged after ET receptor blockade with SB-209670 in 
diabetic rats, implying the blood pressure-independent mech- 
anism for the regulation of cardiac VEGF signaling. We 
confirmed that no significant change was seen in cardiac 
function or LV VEGF expression in nondiabetic control rats 
treated with SB-209670. Furthermore, the specific effect of 
SB-209670 on ET receptors was supported by our preliminary 
experiments showing no difference in VEGF levels between 
cultured neonatal rat ventricular cardiomyocytes with or with- 
out treatment with SB-209670. 
In the present study, total myocardial protein extracts were 
used for determination of target molecules, which is similar to 
other studies addressing VEGF signaling in diabetic animal 
models (6, 45, 57). To gain more information on changes in the 
downstream molecules of VEGF angiogenic signaling, phos- 
phorylated Akt and phosphorylated eNOS, in the diabetic 
heart, we performed immunofluorescence staining and found 
that phosphorylated Akt and phosphorylated eNOS were mark- 
edly downregulated in diabetic rat coronary endothelial cells 
and this downregulation was greatly improved by SB-209670. 
From the practical view point, it is difficult to create an 
environment in coronary endothelial cells simulating the 
present in vivo study condition to directly assess downregula- 
tion of the downstream molecules of VEGF angiogenic signal- 
ing. In addition, future studies should focus on exploring the 
upstream molecules that contribute to downregulation of the 
cardiac VEGF signaling cascade in diabetic rats. Further stud- 
ies would be also required to shed light to the mechanistic 
insights into ET antagonist-mediated improvement of diabetic 
cardiomyopathy. 
For the clinical assessment of our diabetic rat model, we 
observed the retina, kidney, and penile tissue in the current 
experimental setting. It should be noted that, at this diabetic 
stage, there was no morphological abnormality in retina. How- 
ever, retinal VEGF expression was increased ~35%, which 
was significantly normalized by the blockade of ET receptors 
(31, 32). Although the VEGF expression level in the whole 
kidney was not significantly upregulated, renal NO levels 
declined but were reversed by SB-209670 (unpublished obser- 
vation). Similar to our previous report, we found a significant 
decrease in VEGF and NO levels in the penile tissues (23), 
which was greatly improved by SB-209670 (unpublished ob- 
servation). In light of the findings presented in this study, 
together with the above unpublished observations, we suggest 
that the ET-1 blockade may be a potential therapeutic approach 
to prevent diverse diabetic complications seen from the early 
stage. 
Recently, we have demonstrated in a conference proceeding 
that, in the 2-wk streptozotocin-induced diabetic heart without 
any significant impairment in cardiac function, the downregu- 
lated gene expression of VEGF was normalized by a selective 
ETA receptor blocker, whereas the downregulated VEGF re- 
ceptor gene expression was not recovered (26). These obser- 
vations have led us to use a dual ET receptor antagonist in the 
present study. We showed that both ETA and ETB receptor 
antagonism is effective in normalizing the defects in VEGF 
angiogenic signaling and the accompanied cardiac dysfunction 
in early streptozotocin-induced diabetic rats. Thus it seems to 
be important to block both ET receptors for the normalization 
of the impairment in VEGF signaling in early type I diabetic 
heart. 
Finally, our present study cannot directly point out the defect 
and downregulation of VEGF angiogenic signaling cascade to 
be the crucial cause to initiate and aggravate diabetic cardio- 
myopathy. As a result, the present findings cannot make any 
cause and effect conclusions about VEGF preventing the car- 
diomyopathy. These findings are corollary. This limitation of 
interpretation should be clearly taken into consideration before 
making any solid conclusion from the current findings. 
In conclusion, data presented herein may imply that, in type 
1 diabetes, downregulation and deficiency of cardiac VEGF 
and its signaling pathways may play a key role in the initiation 
and aggravation of diabetic cardiomyopathy resulting from 
impaired cardiac microvasculature, that ET antagonist can 
confer protection against type 1 diabetic cardiomyopathy, and 
that it also protects VEGF levels. From a molecular point of 
view, we showed for the first time the potential usefulness of 
the ET receptor blocker to prevent the development of diabetic 
cardiovascular complications. 
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